Those with a high CD8+ T/Treg cell ratio exhibited a shorter time to progression into active MM with respect to the cases with low ratios (median progression-free survival (PFS) at 2 years, 38% versus 88%; P = 0.005; Fig. 5f,g and Extended Data Fig. 7a). This evidence concerns the gene CD8A and Miyoshi myopathy.